Go Pro
→ This AI Stock Reminds One Analyst of Early Nvidia (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$17.12
+0.1%		$23.87
$11.92
▼
$27.31
$3.20B1.083.15 million shs3.22 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$107.97
+33.7%		$74.85
$41.50
▼
$118.84
$3.61B3.25820,867 shs3.52 million shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$9.63
-1.9%		$10.95
$6.65
▼
$36.26
$859.23M1.98982,780 shs1.07 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$41.52
+4.3%		$46.97
$29.45
▼
$60.91
$3.20B1.931.29 million shs1.47 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.06%-7.56%-34.41%-15.50%+30.39%
GRAIL, Inc. stock logo
GRAL
GRAIL
+33.68%+42.95%+35.74%+76.68%+159.23%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-1.93%-6.41%-9.92%-8.55%+17.87%
Veracyte, Inc. stock logo
VCYT
Veracyte
+4.35%+0.75%-1.87%-22.81%+21.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$17.12
+0.1%		$23.87
$11.92
▼
$27.31
$3.20B1.083.15 million shs3.22 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$107.97
+33.7%		$74.85
$41.50
▼
$118.84
$3.61B3.25820,867 shs3.52 million shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$9.63
-1.9%		$10.95
$6.65
▼
$36.26
$859.23M1.98982,780 shs1.07 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$41.52
+4.3%		$46.97
$29.45
▼
$60.91
$3.20B1.931.29 million shs1.47 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.06%-7.56%-34.41%-15.50%+30.39%
GRAIL, Inc. stock logo
GRAL
GRAIL
+33.68%+42.95%+35.74%+76.68%+159.23%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-1.93%-6.41%-9.92%-8.55%+17.87%
Veracyte, Inc. stock logo
VCYT
Veracyte
+4.35%+0.75%-1.87%-22.81%+21.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.81
Moderate Buy$32.1787.89% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$70.30-34.89% Downside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.77
Moderate Buy$40.60321.60% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.82
Moderate Buy$55.7834.34% Upside

Current Analyst Ratings Breakdown

Latest OLMA, DYN, GRAL, and VCYT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$84.00
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSector Perform$84.00
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/15/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/14/2026
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$48.00 ➝ $30.00
9/9/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$45.00 ➝ $36.00
9/9/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$52.00 ➝ $65.00
9/9/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$105.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$30.00 ➝ $26.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$35.00 ➝ $30.00
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M32.77N/AN/A$66.13 per share1.63
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$5.88 per shareN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
$517.15M6.45$1.55 per share26.72$16.57 per share2.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$162.45M-$2.12N/AN/AN/AN/A-48.26%-43.04%11/9/2026 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.4129.4526.96N/A20.37%9.26%8.61%11/3/2026 (Estimated)

Latest OLMA, DYN, GRAL, and VCYT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.5515-$0.61-$0.0585-$0.61N/AN/A
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
7/30/2026Q2 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.4103$0.54+$0.1297$0.31$144.59 million$150.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
0.01
8.86
8.86
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.16
8.80

Institutional Ownership

CompanyInstitutional Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
12.56%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
258186.75 million169.08 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
15087.50 million76.51 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
75580.39 million79.11 millionOptionable

Recent News About These Companies

Veracyte Acquires Convergent Genomics For Up To $180 Million To Add Urinary Tumor DNA Bladder Cancer Platform
 |  pulse2.comP
Bank of America Corp DE Invests $64.74 Million in Veracyte, Inc. $VCYT
September 20 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-invests-6474-million-in-veracyte-inc-vcyt-2026-09-20/
Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)
September 19 at 5:08 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CHE/pressreleases/4677087/analysts-have-conflicting-sentiments-on-these-healthcare-companies-veracyte-vcyt-iqvia-holdings-iqv-and-chemed-che/
Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT
September 19 at 3:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-sells-49301-shares-of-veracyte-inc-vcyt-2026-09-19/
Jens Holstein Sells 5,000 Shares of Veracyte (NASDAQ:VCYT) Stock
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031330
Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-has-952-million-holdings-in-veracyte-inc-vcyt-2026-09-17/
Veracyte (NASDAQ:VCYT) Director Jens Holstein Sells 5,000 Shares
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-veracyte-nasdaq-vcyt-director-jens-holstein-sells-5000-shares-2026-09-16/
Shattuck Labs (NASDAQ:STTK) & Veracyte (NASDAQ:VCYT) Financial Comparison
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027064
Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Analysts
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025833
Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-veracyte-inc-nasdaq-vcyt-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-09-16/
Veracyte Adds Another Stream to Bladder Franchise, UBS Says
September 15, 2026  |  marketscreener.comM
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946434-veracyte-inc-vcyt-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Veracyte, Inc.: Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
September 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69580720-veracyte-inc-veracyte-acquires-convergent-genomics-expanding-its-urology-diagnostics-portfolio-with-a-urinary-tumor-dna-testing-platform-399.htm
Veracyte Buys Convergent Genomics
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/veracyte-buys-convergent-genomics-202232974.html
Veracyte Acquires Convergent Genomics For $150 Mln In Cash
September 14, 2026  |  rttnews.comhttps://www.rttnews.com/3690830/veracyte-acquires-convergent-genomics-for-150-mln-in-cash.aspx
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361535/0/en/veracyte-acquires-convergent-genomics-expanding-its-urology-diagnostics-portfolio-with-a-urinary-tumor-dna-testing-platform.html
Why (VCYT) Price Action Is Critical for Tactical Trading
September 13, 2026  |  news.stocktradersdaily.comN
Veracyte (NASDAQ:VCYT) Upgraded at UBS Group
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-veracyte-nasdaq-vcyt-upgraded-at-ubs-group-2026-09-12/
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
September 9, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9073988/veracyte-inc-vcyt-shares-surge-33-what-gf-score-of-81-tells-investors
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes
September 9, 2026  |  zacks.comhttps://www.zacks.com/commentary/2986737/3-medical-instruments-stocks-banking-on-genai-to-tackle-industry-woes?cid=cs-stocknewsapi-ft-industry_outlook-2986737
Insider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares
September 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-vcyt-insider-buying-and-selling-2026-09-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Desk with a monitor showing an upward stock price chart, printed financial reports, and a bronze bull statue.
3 Earnings Season Winners That Analysts Can't Stop Upgrading
By Dan Schmidt | September 7, 2026
A rubber stamp reading "Dividends" rests beside a stamped document, stacked coins, and US currency.
3 Closed-End Funds to Maximize Dividend Payments
By Nathan Reiff | August 23, 2026
Digital illustration of glowing servers, cloud icons, and data charts connected by light streams, symbolizing cloud computing and data networks.
3 Software Stocks Rebounding as AI Fears Give Way to Growth
By Leo Miller | September 21, 2026
Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$17.12 +0.01 (+0.06%)
As of 09/21/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$107.97 +27.20 (+33.68%)
As of 09/21/2026 04:00 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$9.63 -0.19 (-1.93%)
As of 09/21/2026 04:00 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$41.52 +1.73 (+4.35%)
As of 09/21/2026 04:00 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas